Literature DB >> 7074625

Hypogonadism in male patients with metastatic cancer prior to chemotherapy.

R T Chlebowski, D Heber.   

Abstract

Gonadal hormonal function was assessed in 44 adult males with disseminated cancer prior to chemotherapeutic treatment of their cancer by determination of plasma testosterone, free testosterone, and luteinizing hormone (LH) levels. Low values for both testosterone (43% decreased) and free testosterone (66% decreased) were seen in this largely malnourished cancer population, in which 82% of patients were less than 90% of ideal body weight. Four patients of serum testosterone and LH were seen: (a) normal testosterone and normal LH (12 cases); (b) normal testosterone and high LH (13 cases), consistent with early primary hypogonadism; (c) low testosterone and high LH (10 cases), consistent with frank primary hypogonadism; (d) low testosterone and normal or low LH (9 cases), consistent with secondary hypogonadism. Significantly decreased ideal body weight was found in the group with low testosterone and low or normal LH level. We conclude that decreased gonadal hormone secretion is frequently seen in adult males with advanced cancer and malnutrition even prior to chemotherapy treatment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7074625

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

Review 1.  Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies.

Authors:  Kimberlee Burckart; Sorin Beca; Randall J Urban; Melinda Sheffield-Moore
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-07       Impact factor: 4.294

2.  Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial.

Authors:  E Del Fabbro; J M Garcia; R Dev; D Hui; J Williams; D Engineer; J L Palmer; L Schover; E Bruera
Journal:  Support Care Cancer       Date:  2013-05-08       Impact factor: 3.603

3.  Luteinizing hormone pulsatility and computer-assisted analysis of sperm features in patients with Hodgkin's disease.

Authors:  M Magnanti; S Malizia; G Garufi; A Lenzi; A P Anselmo; F Beligotti; A Fabbrini; V Santiemma
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Serum concentrations of sex hormone binding globulin in lung cancer.

Authors:  T P Corbishley; J J Keating; P J Johnson; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-27

Review 5.  A systematic review of opioid effects on the hypogonadal axis of cancer patients.

Authors:  Kerry McWilliams; Claribel Simmons; Barry J Laird; Marie T Fallon
Journal:  Support Care Cancer       Date:  2014-03-15       Impact factor: 3.603

Review 6.  When and when not to use testosterone for palliation in cancer care.

Authors:  Rony Dev; Eduardo Bruera; Egidio Del Fabbro
Journal:  Curr Oncol Rep       Date:  2014-04       Impact factor: 5.075

7.  Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.

Authors:  Andrew J Weickhardt; Robert C Doebele; W Thomas Purcell; Paul A Bunn; Ana B Oton; Micol S Rothman; Margaret E Wierman; Tony Mok; Sanjay Popat; Julie Bauman; Jorge Nieva; Silvia Novello; Sai-Hong Ignatius Ou; D Ross Camidge
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

8.  Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer.

Authors:  Rony Dev; David Hui; Egidio Del Fabbro; Marvin O Delgado-Guay; Nikhil Sobti; Shalini Dalal; Eduardo Bruera
Journal:  Cancer       Date:  2014-02-27       Impact factor: 6.860

Review 9.  Biomarkers for cancer cachexia: is there also a genetic component to cachexia?

Authors:  B H L Tan; D A C Deans; R J E Skipworth; J A Ross; K C H Fearon
Journal:  Support Care Cancer       Date:  2007-12-11       Impact factor: 3.603

10.  Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function.

Authors:  Jaap J M Teunissen; Eric P Krenning; Frank H de Jong; Yolanda B de Rijke; Richard A Feelders; Maarten O van Aken; Wouter W de Herder; Dik J Kwekkeboom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.